局部区域复发食管癌患者再程放疗的生存获益:倾向性评分匹配分析
该回顾性分析纳入87例初诊接受放疗的食管鳞状细胞癌患者,比较再程放疗与其他治疗对总生存的影响,并用倾向性评分模型平衡基线协变量;中位随访87个月,39例接受再程放疗,Cox多因素分析显示失败模式与再程放疗是总生存的独立预后因素。
要点
- 再程放疗组发生放射性肺炎的比例高于非再程放疗组(24.24% vs 6.06%,P=0.039),但无肺炎相关死亡。
- 匹配队列中Cox模型显示失败模式与再程放疗为预后因素,风险比分别为0.319(P=0.025)和0.375(P=0.002)。
- 再程放疗联合化疗相较单纯再程放疗未显示生存获益(P=0.70)。
核心结论
- 再程放疗改善了局部区域复发食管鳞状细胞癌患者的长期生存。
- 尽管放射性肺炎发生率较高,毒性仍可耐受。
研究设计与样本
- 回顾性分析87例初诊接受放疗的食管鳞状细胞癌患者,失败模式分为单纯区域淋巴结复发(LN)与原发性失败伴或不伴区域淋巴结复发(PF)。
- 患者接受再程放疗或其他治疗(非再程放疗组),基线协变量通过倾向性评分模型平衡,评估总生存与毒性。
主要发现
- 中位随访时间为87个月,39例患者接受再程放疗。
- Cox多因素分析显示失败模式与再程放疗是总生存的独立预后因素(P=0.040和P=0.015)。
- 再程放疗联合化疗相较单纯再程放疗未显示生存获益(P=0.70)。
- 倾向性评分匹配后卡方检验显示组间特征无差异,匹配队列Cox模型显示失败模式与再程放疗的风险比分别为0.319(P=0.025)和0.375(P=0.002)。
- 按失败模式(P=0.004)与再程放疗(P<0.001)分层,总生存差异显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To investigate the treatment failure pattern and factors influencing locoregional recurrence of esophageal squamous cell carcinoma (ESCC) and examine patient survival with re-irradiation (re-RT) after primary radiotherapy. METHODS: We retrospectively analyzed 87 ESCC patients treated initially with radiotherapy. Failure patterns were classified into regional lymph node recurrence only (LN) and primary failure with/without regional lymph node recurrence (PF). Patients received either re-RT or other treatments (non-re-RT group). Baseline covariates were balanced by a propensity score model. Overall survival (OS) and toxicities were assessed as outcomes. RESULTS: The median follow-up time was 87 months. Thirty-nine patients received re-RT. Failure pattern and re-RT were independent prognostic factors for OS (P = 0.040 and 0.015) by Cox multivariate analysis. Re-RT with concomitant chemotherapy showed no survival benefit over re-RT alone (P = 0.70). No differences in characteristics were found between the groups by Chi-square tests after propensity score matching. The Cox model showed that failure pattern and re-RT were prognostic factors with hazard ratios (HR) of 0.319 (P = 0.025) and 0.375 (P = 0.002), respectively, in the matched cohort. Significant differences in OS were observed according to failure pattern (P = 0.004) and re-RT (P < 0.001). In the re-RT and non-re-RT groups, 9.09% and 3.03% of patients experienced tracheoesophageal fistulas, and 15.15% and 3.03% of patients developed pericardial/pleural effusion, respectively (P > 0.05). The incidence of radiation pneumonitis was higher in the re-RT group (24.24% vs. 6.06%, P = 0.039), but no cases of pneumonia-related death occurred. CONCLUSIONS: Re-RT improved long-term survival in patients with locoregional recurrent ESCC. Despite a high incidence of radiation pneumonitis, toxicities were tolerable.
引用
- Hong L, Huang YX, Zhuang QY, et al. Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis. Radiat Oncol. 2018. PMID: 30201005. doi:10.1186/s13014-018-1122-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。